Three people who work at some companies bought more shares of their own company because they think it's a good idea. This is called "insider buying". The article talks about two other stocks, Rocket Companies and CION Invt, but only the first one has insider buying happening right now. Some analysts also gave opinions on these companies, saying they might be worth more in the future. Read from source...

- The title is misleading and sensationalized, as it implies that insiders are buying the stock because they have some insider knowledge or confidence in the company, which may not be true. Insiders can buy or sell stocks for various reasons, such as diversifying their portfolio, managing their cash flow, or hedging against risk.
- The article does not provide any context or background information about Outlook Therapeutics, CION Invt, or Rocket Companies, which makes it difficult for readers to understand the companies' business models, products, markets, and competitive advantages.
- The article relies on analyst upgrades and downgrades as a source of information, which can be unreliable and subject to conflicts of interest. Analysts may have different incentives, biases, and methodologies that affect their ratings and recommendations, and they may change their opinions over time or based on market conditions.
- The article does not disclose any potential conflicts of interest or compensation arrangements with the companies or individuals mentioned in the article, which can affect the credibility and objectivity of the information presented. For example, the author may have a financial stake in the outcome of the stocks, or receive payments from advertisers or sponsors that influence their content.
- The article does not provide any historical performance data or risk factors for the stocks, which can help readers evaluate the potential returns and risks of investing in them. For example, how has the stock price performed over different time periods? What are the main sources of revenue and profitability for the companies? What are the main challenges and threats they face from competitors or market conditions?
- The article does not offer any actionable advice or strategies for readers to follow, such as when and how to buy or sell the stocks, what price targets or valuation metrics to use, or what factors to monitor for future updates. Instead, it just summarizes the trades of insiders and some analyst opinions, which may not be sufficient or useful for readers who want to make informed decisions.

- Outlook Therapeutics (OTLK): Buy, high growth potential, insider buying indicates confidence in the company and its product ONS-5010. However, there is a high risk involved due to the clinical stage of development and uncertainty about regulatory approval and market adoption.
- CION Invt (CION): Hold, moderate growth potential, insider buying indicates confidence in the company's ability to generate returns for shareholders. However, there is a moderate risk involved due to the high exposure to leveraged loans and the impact of rising interest rates on the investment strategy.
- Rocket Companies (RKT): Sell, low growth potential, insider selling indicates lack of confidence in the company's future prospects and profitability. There is a low risk involved as the stock has already run up significantly since its IPO and the valuation is rich compared to peers.